Group 1 - The company, Longshen Rongfa (300534.SZ), focuses on the research, production, and sales of traditional Chinese medicine [1] - Currently, the company has no business related to brain-machine interfaces [1]

Core Viewpoint - The company will continue to focus on its main business and leverage the advantages of state-owned capital to strengthen its market presence and expand into OTC and untapped areas [1] Group 1: Business Strategy - The company is concentrating on two exclusive core products: Yuanhu Zhitong Pill and Xuanfei Zhiso Mixture, aiming to consolidate its existing market [1] - The company plans to actively expand into the generic drug market, health products line, and medical devices to cultivate new growth points [1] Group 2: Research and Development - The company is committed to increasing R&D investment and enhancing its R&D capabilities, aiming to build a collaborative innovation system and a long-term mechanism for R&D investment [1] - The company will continue to promote the secondary development of its main products while increasing R&D efforts in new drugs, classic formulas, and health-related fields to enrich its product pipeline and enhance core competitiveness [1]

Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. has received official certification for its health product "Huangqi Danggui Capsules" from the Macao Special Administrative Region, allowing it to enter the Macao market without prior drug import permits, marking a significant milestone in the company's expansion into the Guangdong-Hong Kong-Macao Greater Bay Area and international markets [1][2]. Group 1 - The "Huangqi Danggui Capsules" are made from traditional medicinal materials Huangqi and Danggui, combined with microcrystalline cellulose and silicon dioxide, adhering to traditional Chinese medicine principles and modern formulation techniques, and have been scientifically validated for their protective functions against radiation hazards [1]. - The "Macao Non-Drug Certification" system is a unique regulatory framework established by the Macao government for high-value functional foods and health products, providing a clear pathway for quality health products and facilitating access to markets in Portuguese-speaking countries, the EU, Latin America, and the Middle East [2]. - The recognition of "Huangqi Danggui Capsules" not only serves as an authoritative endorsement of its quality, safety, and efficacy by the Macao government but also signifies a critical step in the company's strategy to internationalize traditional Chinese medicine health products [2]. Group 2 - In recent years, the company has actively expanded its international presence through its wholly-owned subsidiary, Gansu New Silk Road Industrial Investment Co., Ltd., targeting markets in East Asia, Central Asia, Southeast Asia, and Europe, with successful product registration and export sales in Russia, Kyrgyzstan, Singapore, and Thailand [2]. - The company plans to leverage its full industry chain advantages in traditional Chinese medicine cultivation, deep processing, research, and production to enhance product quality and technological innovation, while actively researching and aligning with health product regulations in different countries and regions [3]. - The company aims to provide high-quality health solutions derived from China to global consumers, contributing to the "Healthy China" initiative and the internationalization of traditional Chinese medicine [3].

Group 1 - The company announced the approval of the proposal to reappoint the accounting firm for the fiscal year 2025 during the sixth extraordinary general meeting of shareholders [2]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-083 甘肃陇神戎发药业股份有限公司 2025年第六次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议召开时间：2025 年 12 月 19 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年12月19日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易 所互联网投票系统进行网络投票的时间为2025年12月19日9:15—15:00期间的任 意时间。 2.现场会议地点：甘肃省兰州市榆中县定远镇国防路 10 号公司六楼会议室 3.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式召开 4.会议召集人：公司董事会 5.会议主持人：董事长康永红先生 6.本次股东会的召集、召开以及表决程序符合《公司法》等法律、行政法规 ...

北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第六次临时股东会 之 法律意见书 甘肃省兰州市城关区雁园路 601 号甘肃省商会大厦 A 座 15 层 邮编：730030 2025 年第六次临时股东会之 法律意见书 致：甘肃陇神戎发药业股份有限公司 北京德恒（兰州）律师事务所（以下简称"本所"）受甘肃陇神戎发药业股 份有限公司（以下简称"陇神戎发""贵公司""公司"）委托，指派张军、杨 晓楠律师（以下简称"本所律师"）出席贵公司 2025 年第六次临时股东会（以 下简称"本次股东会"），并对本次股东会的合法性出具法律意见书。 本所律师列席了贵公司本次股东会，并根据本法律意见书出具日前已发生或 存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》以及《甘肃 陇神戎发药业股份有限公司章程》（以下简称《公司章程》）等有关法律、法规 和规范性文件的有关规定出具本法律意见书。 为出具本法律意见书，本所律师审查了本次股东会的有关文件和材料。本所 律师已得到贵公司保证，其已提供了本所律师认为出具法律意见书所必需的材料， ...

Core Viewpoint - The company, Longshen Rongfa, reported that as of December 10, 2025, the number of shareholders is expected to reach 26,491 [2] Group 1 - The company is actively engaging with investors through an interactive platform [2] - The projected number of shareholders indicates potential growth and interest in the company [2] - The date mentioned for the shareholder count is specifically set for December 10, 2025, highlighting a future outlook [2]

证券日报网讯12月3日晚间，陇神戎发（300534）发布公告称，公司于2025年12月3日召开第五届董事会 第二十五次会议，审议通过《关于续聘2025年度会计师事务所的议案》，决定续聘希格玛会计师事务所 (特殊普通合伙)为公司2025年度审计机构，该议案尚需提交公司股东会审议。 ...

每经头条（nbdtoutiao）——股民发帖求主力拉涨停，次日竟成真！襄阳轴承涨停迷局背后：平台审核 漏洞与市场操纵疑云发酵 每经AI快讯，陇神戎发12月3日晚间发布公告称，公司第五届第二十五次董事会会议于2025年12月3日 以通讯方式召开。会议审议了《关于续聘2025年度会计师事务所的议案》等文件。 （记者 曾健辉） ...

甘肃陇神戎发药业股份有限公司 重大信息内部报告和保密制度 第一章 总则 第一条 为规范甘肃陇神戎发药业股份有限公司（以下简称"公司"）的重 大信息内部报告工作，保证公司内部重大信息的快速传递、归集和有效管理，及 时、准确、全面、完整地披露信息，维护投资者的合法权益，根据《中华人民共 和国公司法》《中华人民共和国证券法》、中国证监会《上市公司信息披露管理 办法》《深圳证券交易所创业板股票上市规则》（以下简称《上市规则》）、《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以 下简称《规范运作》）以及《公司章程》等有关规定，结合公司实际情况，制定 本制度。 第二条 本制度所指"重大信息"是指所有对公司股票及其衍生品种交易价 格可能或者已经产生较大影响的信息，具体包括但不限于重大交易信息、关联交 易信息、重大经营管理信息及其他重大事项信息等。 第三条 公司实行重大信息实时报告制度。公司各部门、所属子公司出现、 发生或即将发生本制度第二章所述情形时，负有报告义务的人员应将有关信息告 知公司董事会秘书，确保及时、真实、准确、完整、没有虚假、严重误导性陈述 或重大遗漏。 董事会秘书、报告义务人 ...